A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Nura A. Mohamed; Blerina Ahmetaj-Shala; Lucie Duluc; Louise Mackenzie; Nicholas S. Kirkby; Daniel M. Reed; Paul D. Lickiss; Robert P. Davies; Gemma Freeman; Beata Wojciak-Stothard

doi:10.1007/s12265-016-9684-2

A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Nura A. Mohamed, Blerina Ahmetaj-Shala, Lucie Duluc, Louise Mackenzie, Nicholas S. Kirkby, Daniel M. Reed, Paul D. Lickiss, Robert P. Davies, Gemma Freeman, Beata Wojciak-Stothard

University of Brighton

Research output: Contribution to journal › Article › peer-review

Abstract

Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.

Original language	English
Pages (from-to)	162-164
Number of pages	3
Journal	Journal of Cardiovascular Translational Research
Volume	9
Issue number	2
DOIs	https://doi.org/10.1007/s12265-016-9684-2
Publication status	Published - 9 Mar 2016

Bibliographical note

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Access to Document

10.1007/s12265-016-9684-2Licence: CC BY

Mohamed et al March 2016 J Cardiovasc Trans Res.pdfFinal published version, 411 KBLicence: CC BY

Louise MacKenzie
- L.Mackenzie2brighton.acuk
- School of Applied Sciences - Principal Lecturer
- Centre for Lifelong Health
Person: Academic

Cite this

@article{01d07d0ac15f4b83afa471d353a93b41,

title = "A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension",

abstract = "Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.",

author = "Mohamed, {Nura A.} and Blerina Ahmetaj-Shala and Lucie Duluc and Louise Mackenzie and Kirkby, {Nicholas S.} and Reed, {Daniel M.} and Lickiss, {Paul D.} and Davies, {Robert P.} and Gemma Freeman and Beata Wojciak-Stothard",

note = "This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",

year = "2016",

month = mar,

day = "9",

doi = "10.1007/s12265-016-9684-2",

language = "English",

volume = "9",

pages = "162--164",

journal = "Journal of Cardiovascular Translational Research",

issn = "1937-5387",

number = "2",

}

TY - JOUR

T1 - A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

AU - Mohamed, Nura A.

AU - Ahmetaj-Shala, Blerina

AU - Duluc, Lucie

AU - Mackenzie, Louise

AU - Kirkby, Nicholas S.

AU - Reed, Daniel M.

AU - Lickiss, Paul D.

AU - Davies, Robert P.

AU - Freeman, Gemma

AU - Wojciak-Stothard, Beata

N1 - This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PY - 2016/3/9

Y1 - 2016/3/9

N2 - Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.

AB - Pulmonary arterial hypertension (PAH) is a chronicand progressive disease which continues to carry an unacceptablyhigh mortality and morbidity. The nitric oxide (NO) pathwayhas been implicated in the pathophysiology and progressionof the disease. Its extremely short half-life and systemiceffects have hampered the clinical use of NO in PAH. In anattempt to circumvent these major limitations, we have developeda new NO-nanomedicine formulation. The formulationwas based on hydrogel-like polymeric composite NO-releasingnanoparticles (NO-RP). The kinetics of NO release fromthe NO-RP showed a peak at about 120 min followed by asustained release for over 8 h. The NO-RP did not affect theviability or inflammation responses of endothelial cells. TheNO-RP produced concentration-dependent relaxations of pulmonaryarteries in mice with PAH induced by hypoxia. Inconclusion, NO-RP drugs could considerably enhance thetherapeutic potential of NO therapy for PAH.

U2 - 10.1007/s12265-016-9684-2

DO - 10.1007/s12265-016-9684-2

M3 - Article

SN - 1937-5387

VL - 9

SP - 162

EP - 164

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

IS - 2

ER -

A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Abstract

Bibliographical note

Access to Document

Fingerprint

Profiles

Louise MacKenzie

Cite this